Peptide research profile

Pinealon

Also known as EDR · Glu-Asp-Arg

A synthetic tripeptide from the Russian peptide-bioregulator program, proposed for neuroprotective and cognitive research. Controlled independent human evidence is very thin.

  • Cognitive & neural
  • Organ bioregulators
Preclinical-heavy2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 2 mg daily for 10 days row is a recorded bioregulator convention, not a validated cognitive-treatment regimen. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset2 mg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo validated upper exposure
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • 10-day block in the preset

    The cadence represented by the recorded calculator presets.

  • Repeat every 4 months in the source row

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

Human dose-ranging, pharmacokinetic, and long-term safety trials are not established.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Neuronal stress

    Cell and rodent studies examine oxidative stress, apoptosis, and neuronal survival.

  • 02

    Cognition after injury

    Small open-label reports examine memory and attention after brain injury.

  • 03

    Aging biomarkers

    Regional studies combine Pinealon with other interventions in older populations.

  • 04

    Gene regulation

    Laboratory work proposes short-peptide interactions with transcription and chromatin.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Animal

    Prenatal hyperhomocysteinemia model

    Rat-offspring research reported changes in oxidative stress and neuronal cell death.

  • Human

    Small uncontrolled reports

    Published clinical observations lack robust randomization, blinding, and independent replication.

  • Review

    Single-network evidence base

    Most work comes from the originating St Petersburg research group.

Recorded protocol library

Amounts recorded for Pinealon

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    1 mg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    2 mg

    Sign in for schedule, duration and source context.

  • 03

    Dose · upper endpoint

    5 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Synthetic tripeptide bioregulator
Sequence
EDR
Amino acids
3
Approx. MW
418.4 Da
Origin / design
Developed as a short “brain bioregulator” peptide

Important limitations

  • No large randomized, placebo-controlled human trial establishes cognitive benefit.
  • Combination and open-label designs prevent attribution of reported outcomes to Pinealon.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Pinealon protects rat offspring from prenatal hyperhomocysteinemiaInternational Journal of Clinical and Experimental Medicine · 2012 · Animal
  2. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndromeAdvances in Gerontology · 2015 · Human

Related profiles